Epigenomics

ECX

The current Epigenomics (ECX) market capitalization is approximately €789.25K, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Epigenomics's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:43 PM Eastern Time

In the most recently reported quarter, Epigenomics (ECX) generated €68.11K in revenue. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:24 AM Eastern Time

In the most recently reported fiscal year, Epigenomics (ECX) generated net income of €-3.35M, compared with €-4.46M in the prior fiscal year, representing a +24.90% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:24 AM Eastern Time

According to its latest quarterly filing, Epigenomics (ECX) reported EBITDA of €2.30M. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 2:24 AM Eastern Time

In the most recently reported quarter, Epigenomics (ECX) revenue was €68.11K. Earnings per share (EPS) for the quarter were €2.20. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:24 AM Eastern Time

Epigenomics (ECX) does not currently pay a dividend. Over the last twelve months (LTM), the company paid €0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:24 AM Eastern Time

Based on the latest available analyst coverage, Epigenomics (ECX) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated:

Like other publicly traded stocks, Epigenomics (ECX) shares are bought and sold on stock exchanges such as DB and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Epigenomics (ECX) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add ECX to your watchlist.

Epigenomics trades under the ticker symbol ECX on the DB stock exchange. The ticker ECX is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Epigenomics (ECX) employs approximately 3 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:43 PM Eastern Time

Epigenomics (ECX) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Epigenomics (ECX) stock peers based on overlapping products, services, and competitive dynamics:bioMérieux (BIM)MDxHealth (MDXH)Exact Sciences (EXAS)GRAIL (GRAL)Hologic (HOLX)Guardant Health (GH)VolitionRx (VNRX)Becton (BDX)Thermo Fisher Scientific (TMO) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Epigenomics.